Terms: = Lymphoma AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Clinical Outcome
11 results:
1. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma.
Zamani-Ahmadmahmudi M; Nassiri SM; Asadabadi A
Sci Rep; 2021 Oct; 11(1):21098. PubMed ID: 34702929
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience.
Baidoun F; Chen D; Patnaik M; Gangat N; Begna K; Elliott M; Hogan W; Litzow M; Al-Kali A
Leuk Lymphoma; 2019 Oct; 60(10):2483-2487. PubMed ID: 31609151
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract] [Full Text] [Related]
5. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract] [Full Text] [Related]
6. clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
Kamran SC; Jacene HA; Chen YH; Mauch PM; Ng AK
Leuk Lymphoma; 2018 Jun; 59(6):1384-1390. PubMed ID: 28937297
[TBL] [Abstract] [Full Text] [Related]
7. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve clinical outcome and Identify Early Mechanisms of Resistance.
McCoach CE; Bivona TG; Blakely CM; Doebele RC
Clin Lung Cancer; 2016 Sep; 17(5):466-469. PubMed ID: 27378174
[TBL] [Abstract] [Full Text] [Related]
8. Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with met expression.
Koh YW; Yoon DH; Suh C; Cha HJ; Huh J
Int J Exp Pathol; 2015 Aug; 96(4):232-9. PubMed ID: 25916750
[TBL] [Abstract] [Full Text] [Related]
9. Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.
Alley CL; Wang E; Dunphy CH; Gong JZ; Lu CM; Boswell EL; Burchette J; Lagoo AS
Arch Pathol Lab Med; 2013 Apr; 137(4):503-17. PubMed ID: 23544940
[TBL] [Abstract] [Full Text] [Related]
10. The HGF/met pathway as target for the treatment of multiple myeloma and B-cell lymphomas.
Mahtouk K; Tjin EP; Spaargaren M; Pals ST
Biochim Biophys Acta; 2010 Dec; 1806(2):208-19. PubMed ID: 20655987
[TBL] [Abstract] [Full Text] [Related]
11. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
[TBL] [Abstract] [Full Text] [Related]
